Bibliography: Adverse effects of finasteride

This page contains research related to adverse effects of finasteride published since 2000.
See also research by: Symptom | Field of study | Systematic reviews & meta-analyses | Related research
This research briefing summarizes two recent systematic reviews/meta-analyses.

📚 = systematic review / meta-analysis      🧬 = genetics focus      🐀 = animal study

Jump to:
2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2010 | 2005 | 2000 | Early research (1974–1999)

2021

Birch MR, Dissing S, Skakkebæk NE, Rehfeld A. Finasteride interferes with prostaglandin-induced CatSper-signalling in human sperm. Reproduction. 2021 Mar 1:REP-20-0287.R3. doi:10.1530/REP-20-0287 | PubMed

Burgos-Blasco B, Burgos-Blasco P. Macular Abnormalities Associated With 5α-Reductase Inhibitor. JAMA Ophthalmol. 2021 Feb 1;139(2):251-252. doi: 10.1001/jamaophthalmol.2020.5768 | PubMed

Giatti S, Di Domizio A, Diviccaro S, Falvo E, Caruso D, Contini A, Melcangi RC. Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target. Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.0c02039 | PubMed

Kang MJ, Choi JY, Sim WY, Lew BL. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study. J Am Acad Dermatol. 2021 Jan;84(1):172-173. doi:10.1016/j.jaad.2020.04.051 | PubMed

Kim JA, Choi D, Choi S, Chang J, Park SM. The Association of 5α-Reductase Inhibitor With Suicidality. Psychosom Med. 2020 Apr;82(3):331-336. doi:10.1097/PSY.0000000000000784 | PubMed

🐀 Kur P, Kolasa-Wołosiuk A, Grabowska M, Kram A, Tarnowski M, Baranowska-Bosiacka I, Rzeszotek S, Piasecka M, Wiszniewska B. The Postnatal Offspring of Finasteride-Treated Male Rats Shows Hyperglycaemia, Elevated Hepatic Glycogen Storage and Altered GLUT2, IR, and AR Expression in the Liver. Int J Mol Sci. 2021 Jan 27;22(3):1242. doi:10.3390/ijms22031242 | PubMed

La Vignera S, Aversa A, Cannarella R, Condorelli RA, Duca Y, Russo GI, Calogero AE. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother. 2021 Feb;22(2):179-189. doi:10.1080/14656566.2020.1817382 | PubMed

Lusty A, Siemens DR, Tohidi M, Whitehead M, Tranmer J, Nickel JC. Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study. J Urol. 2021 Feb 22:101097JU0000000000001561. doi:10.1097/JU.0000000000001561 | PubMed

Pompili M, Magistri C, Maddalena S, Mellini C, Persechino S, Baldessarini RJ. Risk of Depression Associated With Finasteride Treatment. J Clin Psychopharmacol. 2021 Mar 31. doi:10.1097/JCP.0000000000001379 | PubMed

Shin YK, Kang SW. Macular Abnormalities Associated With 5α-Reductase Inhibitor-Reply. JAMA Ophthalmol. 2021 Feb 1;139(2):252-253. doi:10.1001/jamaophthalmol.2020.5774 | PubMed

2020

🐀 Ahire A, Nair, KP, Shankaranarayana Rao BS, Srikumar BN. The Potential Involvement of Cholinergic System in Finasteride Induced Cognitive Dysfunction. Psychoneuroendocrinology. 2020:105066. In press 18 Nov 2020. doi:10.1016/j.psyneuen.2020.105066 | PubMed

Albasher G, Bin-Jumah M, Alfarraj S, et al. Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women. Biosci Rep. 2020;40(2):BSR20191434. doi:10.1042/BSR20191434PubMed

Alcántara Montero A, Müller-Arteaga C. 5-alpha reductase inhibitors: New evidences on benefits and harms beyond benign prostatic hyperplasia. Inhibidores de la 5-alfa reductasa: nuevas evidencias sobre los beneficios y los daños más allá de la hiperplasia benigna de próstata. Actas Urol Esp. 2019;43(1):52-53. doi:10.1016/j.acuro.2018.05.003 | PubMed

🐀 Angrimani DSR, Bicudo LC, Llamas Luceño N, et al. Does finasteride treatment for benign prostatic hyperplasia influence sperm DNA integrity in dogs?. Basic Clin Androl. 2020;30:9. doi:10.1186/s12610-020-00108-2 | PubMed

🐀 Angrimani DSR, Brito MM, Rui BR, Nichi M, Vannucchi CI. Reproductive and endocrinological effects of Benign Prostatic Hyperplasia and finasteride therapy in dogs. Sci Rep. 2020;10(1):14834. doi:10.1038/s41598-020-71691-7PubMed

🐀 Angrimani DSR, Francischini MCP, Brito MM, Vannucchi CI. Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy. PLoS One. 2020;15(6):e0234714. doi:10.1371/journal.pone.0234714 | PubMed

🐀 Bartolomé I, Llidó A, Darbra S, Pallarès M. Early postnatal neuroactive steroid manipulation differentially affects recognition memory and passive avoidance performance in male rats. Behav Brain Res. 2020;112833. doi:10.1016/j.bbr.2020.112833 | PubMed

Borgo F, Macandog AD, Diviccaro S, Falvo E, Giatti S, Cavaletti G, Melcangi RC. Alterations of gut microbiota composition in post-finasteride patients: a pilot study. J Endocrinol Invest. 2020 Sep 19. doi:10.1007/s40618-020-01424-0 | PubMed

📚 Busetto GM, Del Giudice F, D’Agostino D, et al. Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature. Arch Ital Urol Androl. 2020;91(4):205-210. doi:10.4081/aiua.2019.4.205 | PubMed

📚 Chen L, Zhang J, Wang L, Wang H, Chen B. The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. Aesthetic Plast Surg. 2020 Jun;44(3):962-970. doi:10.1007/s00266-020-01621-5 | PubMed

🐀 Chen X, Feng H, El-Kott AF, Abd-Ella EM. Origanum vulgare L. leaves extract alleviates testis and sperm damages induced by finasteride: Biochemical, Immunohistological and apoptosis genes based evidences. Andrologia. 2020 Sep 23:e13823. doi:10.1111/and.13823 | PubMed

Deng T, Duan X, He Z, Zhao Z, Zeng G. Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis. Urol J. 2020;10.22037/uj.v16i7.5866. doi:10.22037/uj.v16i7.5866 | PubMed

Dhurat R, Sharma A, Rudnicka L, et al. 5-alpha Reductase Inhibitors in Androgenetic Alopecia: Shifting Paradigms, Current Concepts, Comparative Efficacy and Safety. Dermatol Ther. 2020;10.1111/dth.13379. doi:10.1111/dth.13379PubMed

Dyson TE, Cantrell MA, Lund BC. Lack of Association Between 5α-Reductase Inhibitors and Depression. J Urol. 2020;101097JU0000000000001079. doi:10.1097/JU.0000000000001079 | PubMed

Fang Q, Chen P, Du N, Nandakumar KS. Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia. Clin Breast Cancer. 2019;19(5):e624-e636. doi:10.1016/j.clbc.2019.04.006 | PubMed

🐀 Gilroy ÈAM, Bartlett AJ, Gillis PL, et al. Toxicity of the pharmaceuticals finasteride and melengestrol acetate to benthic invertebrates. Environ Sci Pollut Res Int. 2020;10.1007/s11356-020-10121-7. doi:10.1007/s11356-020-10121-7 | PubMed

🐀 Golchin-Rad K, Mogheiseh A, Nazifi S, Ahrari Khafi MS, Derakhshandeh N, Abbaszadeh-Hasiri M. Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride. Top Companion Anim Med. 2020;38:100405. doi:10.1016/j.tcam.2020.100405 | PubMed

🐀 Gul A, Altinay S, Kabasakal L, Yavuz A, Semercioz A, Serefoglu EC. Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatment. Aging Male. 2020 Jun;23(2):161-167. doi:10.1080/13685538.2020.1739019 | PubMed

Gupta MA, Vujcic B, Gupta AK. Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System. Skinmed. 2020;18(3):146-150. PubMed

Harrell MB, Ho K, Te AE, Kaplan SA, Chughtai B. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. World J Urol. 2020;10.1007/s00345-020-03314-9. doi:10.1007/s00345-020-03314-9 | PubMed

📚 Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, de León-Gutiérrez H, Ocampo-Garza SS, Gómez-Flores M, Grimalt R. Efficacy of Intralesional and Oral Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review. Skin Appendage Disord. 2020 Nov;6(6):338-345. doi:10.1159/000510697 | PubMed

Ho RS. Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia. JAMA Dermatol. 2020 Nov 11. doi:10.1001/jamadermatol.2020.3384 | PubMed

Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date. Drug Des Devel Ther. 2020 Mar 2;14:951-959. doi:10.2147/DDDT.S240615 | PubMed

Ihentuge C, Csoka A. Epigenetic Effects of Finasteride on Human Leydig Cells. The FASEB Journal. 2020;34(S1). doi:10.1096/fasebj.2020.34.s1.03823

Irwig MS. Finasteride and Suicide: A Postmarketing Case Series. Dermatology. 2020:1-6. doi:10.1159/000505151 | PubMed

Khera M, Than JK, Anaissie J, et al. Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia. Transl Androl Urol. 2020;9(3):1201-1209. doi:10.21037/tau.2020.03.21 | PubMed

Kim JH, Shim SR, Khandwala Y, Del Giudice F, Sorensen S, Chung BI. Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis. World J Mens Health. 2020 Oct;38(4):535-544. doi:10.5534/wjmh.190046 | PubMed

Kim YJ, Tae BS, Bae JH. Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms. Int Neurourol J. 2020 Sep;24(3):231-240. doi:10.5213/inj.2040082.041 | PubMed

Kjærulff TM, Ersbøll AK, Pukkala E, et al. Characteristics of finasteride users in comparison with nonusers: A Nordic nationwide study based on individual-level data from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf. 2020;10.1002/pds.4947. doi:10.1002/pds.4947 | PubMed

Kroumpouzos G. Effects of 5-alpha reductase inhibitors on lung function: a reason for discontinuation during COVID-19 pandemic?. Dermatol Ther. 2020;e13535. doi:10.1111/dth.13535 | PubMed

La Vignera S, Aversa A, Cannarella R, et al. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother. 2020;1-11. doi:10.1080/14656566.2020.1817382 | PubMed

Lee YR, Im E, Kim H, et al. Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year. Metabolites. 2020;10(4):E131. doi:10.3390/metabo10040131 | PubMed

🐀 Maldarine JS, Sanches BDA, Santos VA, Cabral ÁS, Lima MLD, Bedolo CM, Calmon MF, Rahal P, Góes RM, Vilamaior PSL, Taboga SR. Postnatal exposure to finasteride causes different effects on the prostate of male and female gerbils. Cell Biol Int. 2020 Jun;44(6):1341-1352. doi:10.1002/cbin.11328 | PubMed

🐀 Mendell AL, Creighton SD, Wilson HA, Jardine KH, Isaacs L, Winters BD, MacLusky NJ. Inhibition of 5α Reductase Impairs Cognitive Performance, Alters Dendritic Morphology and Increases Tau Phosphorylation in the Hippocampus of Male 3xTg-AD Mice. Neuroscience. 2020 Mar 1;429:185-202. doi:10.1016/j.neuroscience.2020.01.011 | PubMed

🐀 Mohebali S, Hayati Roodbari N, Hajihosseini R, Parivar K. The effects of Finasteride on the expression of Dazl, Tsga10, Sycp3, Prm2 genes during spermatogenesis in testes of NMRI mice. Eur Rev Med Pharmacol Sci. 2020;24(15):8160-8163. doi:10.26355/eurrev_202008_22503 | PubMed

Motofei IG, Rowland DL, Tampa M, et al. Finasteride and androgenic alopecia; from therapeutic options to medical implications. J Dermatolog Treat. 2020;31(4):415-421. doi:10.1080/09546634.2019.1595507 | PubMed

Nguyen DD, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, Trinh QD. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. JAMA Dermatol. 2020 Nov 11;157(1):35–42. doi:10.1001/jamadermatol.2020.3385 | PubMed

🐀 Olayinka ET, Adewole KE. In vivo and in silico evaluation of the ameliorative effect of hesperidin on finasteride-induced testicular oxidative stress in Wistar rats. Toxicol Mech Methods. 2020 Oct 1:1-28. doi:10.1080/15376516.2020.1831123 | PubMed

Othonos N, Marjot T, Woods C, Hazlehurst JM, Nikolaou N, Pofi R, White S, Bonaventura I, Webster C, Duffy J, Cornfield T, Moolla A, Isidori AM, Hodson L, Tomlinson JW. Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids. J Clin Endocrinol Metab. 2020 Sep 1;105(9):e3316–28. doi:10.1210/clinem/dgaa408 | PubMed

Pallotti F, Senofonte G, Pelloni M, Cargnelutti F, Carlini T, Radicioni AF, Rossi A, Lenzi A, Paoli D, Lombardo F. Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. Endocrine. 2020 Feb 12. doi:10.1007/s12020-020-02219-2 | PubMed

Pereira AFJR, Coelho TOA. Post-finasteride syndrome. Anais Brasileiros de Dermatologia. 25 March 2020. doi:10.1016/j.abd.2020.02.001 | PubMed

Rivera Mirabal J, Than J, Annaisie J, Antar A, Song W, Losso B, Pastuszak A, Kohn T, Khera M. 124 The persistent effects of 5α-reductase inhibitors used in the treatment of androgenic alopecia on men’s health. J Sex Med. 2020;17(1):S33–S34. doi:10.1016/j.jsxm.2019.11.070

🐀 Shalaby AM, Alabiad MA, El Shaer DF. Resveratrol Ameliorates the Seminiferous Tubules Damages Induced by Finasteride in Adult Male Rats. Microsc Microanal. 2020 Oct 5:1-11. doi:10.1017/S1431927620024514 | PubMed

Shin YK, Lee GW, Kang SW, Kim SJ, Kim AY. Macular Abnormalities Associated With 5α-Reductase Inhibitor. JAMA Ophthalmol. 2020 Jul 1;138(7):732-739. doi:10.1001/jamaophthalmol.2020.1279 | PubMed

[Letter] Sirufo MM, Ginaldi L, De Martinis M. Bone Health Risks Associated with Finasteride and Dutasteride Long-Term Use. World J Mens Health. 2020 Nov 26. doi:10.5534/wjmh.200138 | PubMed

Suchonwanit P, Iamsumang W, Leerunyakul K. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. J Dermatolog Treat. 2020;1-21. doi:10.1080/09546634.2020.1782324 | PubMed

Traish AM. Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm. World J Mens Health. 2020;10.5534/wjmh.200012. doi:10.5534/wjmh.200012 | PubMed

Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020;113(1):21-50. doi:10.1016/j.fertnstert.2019.11.030 | PubMed

Vañó-Galván S, Saceda-Corralo D, Moreno-Arrones OM, Rodrigues-Barata R, Morales C, Gil-Redondo R, Bernárdez-Guerra C, Hermosa-Gelbard Á, Jaén-Olasolo P. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study. Dermatol Ther. 2020 Jan;33(1):e13182. doi: 10.1111/dth.13182 | PubMed

Zhou Z, Cui Y, Wu J, Jin H. Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials. Exp Ther Med. 2020;20(2):1566-1574. doi:10.3892/etm.2020.8851 | PubMed

2019

↑ back to top

🐀 Alkahtane AA, Albasher G, Al-Sultan NK, et al. Long-term treatment with finasteride induces apoptosis and pathological changes in female mice. Hum Exp Toxicol. 2019;38(7):762-774. doi:10.1177/0960327119842195 | PubMed

Andy G, John M, Mirna S, et al. Controversies in the treatment of androgenetic alopecia: The history of finasteride. Dermatol Ther. 2019;32(2):e12647. doi:10.1111/dth.12647 | PubMed

🐀 Baig MS, Kolasa-Wołosiuk A, Pilutin A, et al. Finasteride-Induced Inhibition of 5α-Reductase Type 2 Could Lead to Kidney Damage-Animal, Experimental Study. Int J Environ Res Public Health. 2019;16(10):1726. doi:10.3390/ijerph16101726 | PubMed

🐀 Bartolomé I, Llidó A, Darbra S, Pallarès M. Early postnatal allopregnanolone levels alteration and adult behavioral disruption in rats: Implication for drug abuse. Neurobiol Stress. 2019;12:100208. Published 2019 Dec 27. doi:10.1016/j.ynstr.2019.100208 | PubMed

Catalano A, Martino G, Bellone F, Papalia M, Lasco C, Basile G, Sardella A, Nicocia G, Morabito N, Lasco A. Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride. Clin Drug Investig. 2019 Jan;39(1):97-102. Erratum in: Clin Drug Investig. 2018 Nov 26. doi:10.1007/s40261-018-0720-7PubMed

Coskuner ER, Ozkan B, Culha MG. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. Sex Med Rev. 2019;7(2):277-282. doi:10.1016/j.sxmr.2018.07.003 | PubMed

🐀 Diviccaro S, Giatti S, Borgo F, et al. Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition. Psychoneuroendocrinology. 2019;99:206-215. doi:10.1016/j.psyneuen.2018.09.021PubMed

Diviccaro S, Melcangi RC, Giatti S. Post-finasteride syndrome: An emerging clinical problem. Neurobiol Stress. 2019;12:100209. doi:10.1016/j.ynstr.2019.100209 | PubMed

🐀 Fanni S, Scheggi S, Rossi F, et al. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction. Neurobiol Dis. 2019;121:120–130. doi:10.1016/j.nbd.2018.09.018 | PubMed

🧬 Ghassemi M, Ghaffarpour GH, Ghods S. The effect of GGC and CAG repeat polymorphisms on the androgen receptor gene in response to finasteride therapy in men with androgenetic alopecia. J Res Med Sci. 2019;24:104. doi:10.4103/jrms.JRMS_27_19 | PubMed

🐀 Godar SC, Cadeddu R, Floris G, et al. The Steroidogenesis Inhibitor Finasteride Reduces the Response to Both Stressful and Rewarding Stimuli. Biomolecules. 2019;9(11):749. doi:10.3390/biom9110749 | PubMed

Gray SL, Semla TP. Post-finasteride syndrome. BMJ. 2019;366:l5047. doi:10.1136/bmj.l5047 | PubMed

Haber RS, Gupta AK, Epstein E, Carviel JL, Foley KA. Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study. J Eur Acad Dermatol Venereol. 2019;33(7):1393–1397. doi:10.1111/jdv.15548 | PubMed

Kaczmarek IA, Prost ME, Wasyluk J. Clinical risk factors associated with intraoperative floppy iris syndrome: a prospective study. Int Ophthalmol. 2019;39(3):541‐549. doi:10.1007/s10792-018-0840-3 | PubMed

🐀 Kilic S, Kolukcu E, Erdemir F, Benli I, Arici A. The Effects of Oral 5-alpha Reductase Inhibitors on Penile Intracavernosal Pressures and Penile Morphology in Rat Model. Urology J. 2019; 16(2):205–211. doi:10.22037/uj.v0i0.4164 | PubMed

Kjærulff TM, Ersbøll AK, Green A, Emneus M, Brasso K, Iversen P, Pukkala E, Bolin K, Thygesen LC. Finasteride Use and Risk of Male Breast Cancer: A Case-Control Study Using Individual-Level Registry Data from Denmark, Finland, and Sweden. Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):980-986. doi:10.1158/1055-9965.EPI-18-0904 | PubMed

📚 Lee S, Lee YB, Choe SJ, Lee WS. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2019;99(1):12–17. doi:10.2340/00015555-3035 | PubMed

Lee SG, Park PJ, Lee SR, Koo BH, Byun GY, Kim MJ, Kang HJ, Kim S, Oh BS, Lee YH. Influence of Postoperative Finasteride Therapy on Recurrence of Gynecomastia After Mastectomy in Men Taking Finasteride for Alopecia. Am J Mens Health. 2019 Sep-Oct;13(5):1557988319871423. doi:10.1177/1557988319871423 | PubMed

Maksym RB, Kajdy A, Rabijewski M. Post-finasteride syndrome – does it really exist? Aging Male. 2019;22(4):250–259. doi:10.1080/13685538.2018.1548589 | PubMed

🐀 Maldarine JS, Sanches BDA, Cabral ÁS, et al. Prenatal exposure to finasteride promotes sex-specific changes in gerbil prostate development. Reprod Fertil Dev. 2019;31(11):1719-1729. doi:10.1071/RD19106 | PubMed

Marks DH, Prasad S, De Souza B, Burns LJ, Senna MM. Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris. Am J Clin Dermatol. 2019 Dec 12. doi:10.1007/s40257-019-00493-z | PubMed

🧬 Melcangi RC, Casarini L, Marino M, et al. Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study. Endocr Connect. 2019;8(8):1118-1125. doi:10.1530/EC-19-0199 | PubMed

🐀 Sasibhushana RB, Shankaranarayana Rao BS, Srikumar BN. Repeated finasteride administration induces depression-like behavior in adult male rats. Behav Brain Res. 2019;365:185–189. doi:10.1016/j.bbr.2019.03.006 | PubMed

Shin YS, Karna KK, Choi BR, Park JK. Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. World J Mens Health. 2019;37(2):157–165. doi:10.5534/wjmh.180029 | PubMed

🐀 Sung HH, Yu J, Kang SJ, et al. Persistent Erectile Dysfunction after Discontinuation of 5-Alpha Reductase Inhibitor Therapy in Rats Depending on the Duration of Treatment. World J Mens Health. 2019;37(2):240–248. doi:10.5534/wjmh.180082 | PubMed

📚 Traish AM, Krakowsky Y, Doros G, Morgentaler A. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. Sex Med Rev. 2019;7(1):95-114. doi:10.1016/j.sxmr.2018.06.002 | PubMed

Trüeb RM, Régnier A, Dutra Rezende H, Gavazzoni Dias MFR. Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness? Skin Appendage Disord. 2019;5(5):320-326. doi:10.1159/000497362 | PubMed

Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study. BMJ. 2019;365:l1204. doi:10.1136/bmj.l1204 | PubMed

📚 Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS. Sexual dysfunction in men taking systemic dermatologic medication: A systematic review. J Am Acad Dermatol. 2019;81(1):163-172. doi:10.1016/j.jaad.2019.03.043 | PubMed

📚 Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging. 2019;14:399-406. doi:10.2147/CIA.S192435 | PubMed

2018

↑ back to top

AlSaad D, Lee BH, Al-Obaidly S. Finasteride use during pregnancy and early neonatal outcome: a case report. Int J Clin Pharm. 2018;40(4):803-805. doi:10.1007/s11096-018-0661-5 | PubMed

Antoniou T, Macdonald EM, Yao Z, et al. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. BMC Musculoskelet Disord. 2018;19(1):160. Published 2018 May 22. doi:10.1186/s12891-018-2076-9 | PubMed

Andrade C. Why Odds Ratios Can Be Tricky Statistics: The Case of Finasteride, Dutasteride, and Sexual Dysfunction. J Clin Psychiatry. 2018;79(6). doi:10.4088/JCP.18f12641

Baas WR, Butcher MJ, Lwin A, et al. A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome. Urology. 2018;120:143-149. doi:10.1016/j.urology.2018.06.022 | PubMed

🐀 Da Silva MHA, Costa WS, B Sampaio FJ, De Souza DB. The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model. Asian J Androl. 2018;20(5):505–510. doi:10.4103/aja.aja_28_18 | PubMed

Ganzer CA, Jacobs AR. Emotional Consequences of Finasteride: Fool’s Gold. Am J Mens Health. 2018;12(1):90–95. doi:10.1177/1557988316631624 | PubMed

Giatti S, Diviccaro S, Panzica G, Melcangi RC. Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? Endocrine. 2018;61(2):180-193. doi:10.1007/s12020-018-1593-5 | PubMed

Gupta AK, Carviel J, Gupta MA, Shear NH. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System. J Eur Acad Dermatol Venereol. 2018;32(8):1373-1376. doi:10.1111/jdv.14728 | PubMed

Gupta MA, Vujcic B, Sheridan AD, Gupta AK. 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS). Sleep. 2018 Apr;41(Issue suppl_1):A340–A341. doi:10.1093/sleep/zsy061.916

Healy D, Le Noury J, Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med. 2018;29(3-4):125-134. doi:10.3233/JRS-180744 | PubMed

📚 Kim JH, Baek MJ, Sun HY, et al. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. PLoS One. 2018;13(10):e0203479. Published 2018 Oct 3. doi:10.1371/journal.pone.0203479 | PubMed

Lee JY, Cho KS. Effects of 5-alpha reductase inhibitors: new insights on benefits and harms. Curr Opin Urol. 2018;28(3):288–293. doi:10.1097/MOU.0000000000000497 | PubMed

📚 Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. J Drugs Dermatol. 2018;17(4):457–463. Journal site | PubMed

🐀 Li L, Kang YX, Ji XM, et al. Finasteride inhibited brain dopaminergic system and open-field behaviors in adolescent male rats. CNS Neurosci Ther. 2018;24(2):115-125. doi:10.1111/cns.12781

🐀 Maurice-Gélinas C, Deslauriers J, Monpays C, Sarret P, Grignon S. The 5α-reductase inhibitor finasteride increases suicide-related aggressive behaviors and blocks clozapine-induced beneficial effects in an animal model of schizophrenia. Physiol Behav. 2018;191:65–72. doi:10.1016/j.physbeh.2018.03.036 | PubMed

McVary KT, Rogers T, Mahon J, Gupta NK. Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?. J Sex Med. 2018;15(12):1728–1738. doi:10.1016/j.jsxm.2018.10.006 | PubMed

[Comment] Kaplan SA. Re: Is Sexual Function Better Preserved after Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia?. J Urol. 2020;101097JU0000000000000985. doi:10.1097/JU.0000000000000985

Mervis JS, Borda LJ, Miteva M. “Post-finasteride syndrome”: what to tell our female patients? Br J Dermatol. 2018;179(3):785-786. doi:10.1111/bjd.16658 | PubMed

Rezende HD, Dias MFRG, Trüeb RM. A Comment on the Post-Finasteride Syndrome. Int J Trichology. 2018;10(6):255-261. doi:10.4103/ijt.ijt_61_18 | Free PMC Article

Said MA, Mehta A. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men’s Health. Curr Urol Rep. 2018;19(8):65. doi:10.1007/s11934-018-0814-z | PubMed

Schmutz JL. Dépression et idées suicidaires avec le finastéride [Depression and suicidal thoughts associated with finasteride]. Ann Dermatol Venereol. 2018;145(2):155–156. doi:10.1016/j.annder.2018.01.006 | PubMed

Sorbellini E, Pinto D, Marzani B, Rinaldi F. Drug Treatment for Androgenetic Alopecia: First Italian Questionnaire Survey on What Dermatologists Think about Finasteride. Dermatol Ther (Heidelb). 2018;8(2):259-267. doi:10.1007/s13555-018-0233-6

Than JK, Rodriguez K, Khera M. Post-finasteride Syndrome: A Review of Current Literature. Curr Sex Health Rep.2018;10:152-157. doi:10.1007/s11930-018-0163-4

🧬 Traish, AM. The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption. Curr Sex Health Rep. 2018;10:88–103. doi:10.1007/s11930-018-0161-6

Walf AA, Kaurejo S, Frye CA. Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men. Am J Mens Health. 2018;12(4):900-906. doi:10.1177/1557988317750989

Zhang Y, Xu J, Jing J, Wu X, Lv Z. Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men. Med Sci Monit. 2018;24:7770-7777. doi:10.12659/MSM.913116

2017

↑ back to top

Arif T, Dorjay K, Adil M, Sami M. Dutasteride in Androgenetic Alopecia: An Update. Curr Clin Pharmacol. 2017;12(1):31–35. doi:10.2174/1574884712666170310111125 | PubMed

🧬 Cauci S, Chiriacò G, Cecchin E, et al. Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia. Sex Med. 2017;5(1):e61-e71. doi:10.1016/j.esxm.2016.11.001 | PubMed

📚 Corona G, Tirabassi G, Santi D, et al. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5(4):671-678. doi:10.1111/andr.12353 | PubMed

🐀 Cumberland AL, Palliser HK, Crombie GK, Walker DW, Hirst JJ. Increased anxiety-like phenotype in female guinea pigs following reduced neurosteroid exposure in utero. Int J Dev Neurosci. 2017;58:50–58. doi:10.1016/j.ijdevneu.2017.02.001 | PubMed

Drobnis EZ, Nangia AK. 5α-Reductase Inhibitors (5ARIs) and Male Reproduction. Adv Exp Med Biol. 2017;1034:59–61. doi:10.1007/978-3-319-69535-8_7 | PubMed

Enatsu N, Chiba K, Sumii K, Fukuda T, Okada K, Matsushita K, Fujisawa M. Dutasteride-mediated morphological changes in the genitourinary tract associated with altered expression patterns of the androgen and estrogen receptors in male rats. Andrology. 2017 Mar;5(2):347-353. doi:10.1111/andr.12297 | PubMed

📚 Fertig RM, Gamret AC, Darwin E, Gaudi S. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Dermatol Online J. 2017;23(11). Journal site | PubMed

📚 Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A, Joshi G, Khan SA. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol. 2017 Apr;6(2):295-304. doi:10.21037/tau.2017.03.57 | PubMed

🐀 García-García M, Sánchez-Hernández M, García-Hernández MP, García-Ayala A, Chaves-Pozo E. Role of 5α-dihydrotestosterone in testicular development of gilthead seabream following finasteride administration. J Steroid Biochem Mol Biol. 2017;174:48-55. doi:10.1016/j.jsbmb.2017.07.024 | PubMed

Gupta AK, Carviel J, MacLeod MA, Shear N. Assessing finasteride-associated sexual dysfunction using the FAERS database. J Eur Acad Dermatol Venereol. 2017;31(6):1069-1075. doi:10.1111/jdv.14223 | PubMed

Hagberg KW, Divan HA, Fang SC, Nickel JC, Jick SS. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Epidemiol. 2017;9:83‐91. doi:10.2147/CLEP.S124674 | PubMed

Hagberg KW, Divan HA, Nickel JC, Jick SS. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink. Pharmacotherapy. 2017;37(5):517‐527. doi:10.1002/phar.1925 | PubMed

📚 Jun JEJ, Kinkade A, Tung ACH, Tejani AM. 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Can J Hosp Pharm. 2017;70(2):113-119. doi:10.4212/cjhp.v70i2.1643 | PubMed

Kiguradze T, Temps WH, Yarnold PR, Cashy J, Brannigan RE, Nardone B, Micali G, West DP, Belknap SM. Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride. PeerJ. 2017;5:e3020. doi:10.7717/peerj.3020 | PubMed

Kuhl, H., Wiegratz, I. Das Post-Finasterid-Syndrom. Gynäkologische Endokrinologie. 2017;15:153–163. doi:10.1007/s10304-017-0126-2

🐀 Li K, Zhang C, Yang Z, Wang Y, Si H. Evaluation of a novel dry eye model induced by oral administration of finasteride. Mol Med Rep. 2017;16(6):8763–8770. doi:10.3892/mmr.2017.7754 | PubMed

🐀 Litim N, Morissette M, Caruso D, Melcangi RC, Di Paolo T. Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice. J Steroid Biochem Mol Biol. 2017;174:242‐256. doi:10.1016/j.jsbmb.2017.09.021 | PubMed

Melcangi RC, Santi D, Spezzano R, et al. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. J Steroid Biochem Mol Biol. 2017;171:229-235. doi:10.1016/j.jsbmb.2017.04.003 | PubMed

Motofei IG, Rowland DL, Georgescu SR, et al. Post-Finasteride Adverse Effects in Male Androgenic Alopecia: A Case Report of Vitiligo. Skin Pharmacol Physiol. 2017;30(1):42-45. doi:10.1159/000455972

Motofei IG, Rowland DL, Manea M, Georgescu SR, Păunică I, Sinescu I. Safety Profile of Finasteride: Distribution of Adverse Effects According to Structural and Informational Dichotomies of the Mind/Brain. Clin Drug Investig. 2017;37(6):511-517. doi:10.1007/s40261-017-0501-8

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol. 2017;83(1):47-54. doi:10.4103/0378-6323.188652

🐀 Soni KK, Shin YS, Choi BR, et al. Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kinase 1 and c-Jun N-terminal kinase pathway. Drug Des Devel Ther. 2017;11:2969-2979. doi:10.2147/DDDT.S140543 | PubMed

Teichert M, van Puijenbroek E, Stricker BH. Contraindicated use of 5-alpha-reductase inhibitors in women. Br J Clin Pharmacol. 2017;83(2):429-431. doi:10.1111/bcp.13118 | PubMed

Traish AM. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men. Adv Exp Med Biol. 2017;1043:473-526. doi:10.1007/978-3-319-70178-3_22 | PubMed

Trüeb RM. Discriminating in favour of or against men with increased risk of finasteride-related side effects? Exp Dermatol. 2017;26(6):527-528. doi:10.1111/exd.13155 | PubMed

Voznesensky I, Shaw E, DeLay KJ, Yafi F, Hellstrom, WJG. Benign Prostatic Hyperplasia Treatment Options and Their Effects on Sexual Function. Sexual Medicine Reviews. Jan 2017;5(1):87-102. doi:10.1016/j.sxmr.2016.05.006

Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of Suicidality and Depression With 5α-Reductase Inhibitors. JAMA Intern Med. 2017;177(5):683–691. doi:10.1001/jamainternmed.2017.0089 | PubMed

Welk B, McArthur E, Ordon M, Morrow SA, Hayward J, Dixon S. The risk of dementia with the use of 5 alpha reductase inhibitors. J Neurol Sci. 2017;379:109-111. doi:10.1016/j.jns.2017.05.064 | PubMed

2016

↑ back to top

Arias-Santiago S, Camacho-Martínez FM. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern? [Efectos adversos de los inhibidores de la 5-alfa-reductasa en la alopecia androgenética masculina ¿hay por qué preocuparse?]. Actas Dermosifiliogr. 2016;107(9):709–711. doi:10.1016/j.ad.2016.06.006 | PubMed

🧬 Basaria S, Jasuja R, Huang G, et al. Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss. J Clin Endocrinol Metab. 2016;101(12):4669-4680. doi:10.1210/jc.2016-2726

Santmann J. Letter to the Editor: “Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss.” J Clin Endocrinol Metab. 2017;102(6):2117-2118. doi:10.1210/jc.2016-3491

Bhasin S, Stern E, Basaria S. Response to Letter: “Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss.” J Clin Endocrinol Metab. 2017;102(6):2119-2120. doi:10.1210/jc.2016-3682

Carreño-Orellana N, Moll-Manzur C, Carrasco-Zuber JE, Álvarez-Véliz S, Berroeta-Mauriziano D, Porras-Kusmanic N. Efectos adversos de finasteride: mitos y realidades. Una revisión actualizada [Finasteride adverse effects: An update]. Rev Med Chil. 2016;144(12):1584‐1590. doi:10.4067/S0034-98872016001200010 | PubMed

Chiriacò G, Cauci S, Mazzon G, Trombetta C. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Andrology. 2016;4(2):245-250. doi:10.1111/andr.12147

🐀 Corbin CJ, Legacki EL, Ball BA, Scoggin KE, Stanley SD, Conley AJ. Equine 5α-reductase activity and expression in epididymis. J Endocrinol. 2016;231(1):23-33. doi:10.1530/JOE-16-0175

📚 Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19(3):175-181. doi:10.1080/13685538.2016.1195361

Fertig R, Shapiro J, Bergfeld W, Tosti A. Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome. Skin Appendage Disord. 2016;2(3-4):120-129. doi:10.1159/000450617 | PubMed

Finasteride 1 mg in alopecia: sexual dysfunction, suicidal ideation. Prescrire Int. 2016;25(175):242. Journal site

Fiuk, J., Butcher, M., Kohler, T., & McVary, K. (2016). 133 Female Post-Finasteride Syndrome: It’s Not Just A Man’s World. Journal Sex Med, S62-S63. doi:10.1016/j.jsxm.2016.02.139

Füllhase C, Schneider MP. 5-Alpha-Reductase Inhibitors and Combination Therapy. Urol Clin North Am. 2016;43(3):325-336. doi:10.1016/j.ucl.2016.04.003 | PubMed

Garreton, A. S., Valzacchi, G. R., & Layus, O. Post-Finasteride Syndrome: About 2 Cases and Review of the Literature. Andrology-Open Access. 2016;5(2):170. doi:10.4172/2472-1212.1000170 | Journal site

🐀 Giatti S, Foglio B, Romano S, et al. Effects of Subchronic Finasteride Treatment and Withdrawal on Neuroactive Steroid Levels and Their Receptors in the Male Rat Brain. Neuroendocrinology. 2016;103(6):746-757. doi:10.1159/000442982 | PubMed

Guo M, Heran B, Flannigan R, Kezouh A, Etminan M. Persistent Sexual Dysfunction with Finasteride 1 mg Taken for Hair Loss. Pharmacotherapy. 2016;36(11):1180-1184. doi:10.1002/phar.1837 | PubMed

Gupta AK, Sharma N, Shukla P. Atypical post-finasteride syndrome: A pharmacological riddle. Indian J Pharmacol. 2016;48(3):316–317. doi:10.4103/0253-7613.182898 | PubMed

Hagberg KW, Divan HA, Persson R, Nickel JC, Jick SS. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. BMJ. 2016;354:i4823. doi:10.1136/bmj.i4823 | PubMed

[Comment] Gupta NK, McVary KT. Re: Risk of Erectile Dysfunction Associated with Use of 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population Based Studies Using the Clinical Practice Research Datalink. Eur Urol. 2017;72(2):317–318. doi:10.1016/j.eururo.2017.03.043 | PubMed

Hazlehurst JM, Oprescu AI, Nikolaou N, et al. Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man. J Clin Endocrinol Metab. 2016;101(1):103–113. doi:10.1210/jc.2015-2928 | PubMed

📚 Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review. J Clin Aesthet Dermatol. 2016;9(7):56-62. PubMed

Kaplan SA, Lee JY, Meehan AG, Kusek JW. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial. J Urol. 2016;195(6):1825-1829. doi:10.1016/j.juro.2015.11.065 | PubMed

📚 La Torre A, Giupponi G, Duffy D, Conca A, Cai T, Scardigli A. Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs. Pharmacopsychiatry. 2016;49(1):3-13. doi:10.1055/s-0035-1565100

📚 Liu L, Zhao S, Li F, et al. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. J Sex Med. 2016;13(9):1297-1310. doi:10.1016/j.jsxm.2016.07.006 | PubMed

[Comment] Kaplan SA. Re: Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. J Urol. 2018;199(1):8-9. doi:10.1016/j.juro.2017.09.133

🐀 Llidó A, Bartolomé I, Darbra S, Pallarès M. Neonatal finasteride administration decreases dopamine release in nucleus accumbens after alcohol and food presentation in adult male rats. Behav Brain Res. 2016;309:44-50. doi:10.1016/j.bbr.2016.04.047 | PubMed

Molina-Leyva A, Caparros-Del Moral I, Gomez-Avivar P, Alcalde-Alonso M, Jimenez-Moleon JJ. Psychosocial Impairment as a Possible Cause of Sexual Dysfunction among Young Men with Mild Androgenetic Alopecia: A Cross-sectional Crowdsourcing Web-based Study. Acta Dermatovenerol Croat. 2016;24(1):42-48. Europe PMC | Journal site

Motofei IG, Rowland DL, Georgescu SR, Tampa M, Baleanu BC, Paunica S. Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia? Exp Dermatol. 2016;25(7):557-558. doi:10.1111/exd.13003 | PubMed

Motofei IG, Rowland DL, Georgescu SR, et al. Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain. J Dermatolog Treat. 2016;27(6):495-497. doi:10.3109/09546634.2016.1161155 | PubMed

Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82(2):128–134. doi:10.4103/0378-6323.177432 | PubMed

Oelke M, Martinelli E. [Pharmacological treatment of benign prostatic hyperplasia]. Urologe A. 2016;55(1):81-94; quiz 95-96. doi:10.1007/s00120-015-0011-3

Pirozzi Farina F, Pischedda A. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs. Arch Ital Urol Androl. 2016;87(4):312-316. doi:10.4081/aiua.2015.4.312

Seale LR, Eglini AN, McMichael AJ. Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review. J Drugs Dermatol. 2016;15(4):414-419. Journal site

Soggiu A, Piras C, Greco V, et al. Exploring the neural mechanisms of finasteride: a proteomic analysis in the nucleus accumbens. Psychoneuroendocrinology. 2016;74:387–396. doi:10.1016/j.psyneuen.2016.10.001 | PubMed

Unger JM, Till C, Thompson IM, et al. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2016;108(12). doi:10.1093/jnci/djw168 | PubMed

Welliver C, Essa A. Sexual Side Effects of Medical and Surgical Benign Prostatic Hyperplasia Treatments. Urol Clin North Am. 2016;43(3):393–404. doi:10.1016/j.ucl.2016.04.010 | PubMed

Wu M, Yu Q, Li Q. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 2016;7(50):82074-82084. doi:10.18632/oncotarget.12617 | PubMed

2015

↑ back to top

Ali AK, Heran BS, Etminan M. Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study. Pharmacotherapy. 2015;35(7):687-695. doi:10.1002/phar.1612 | PubMed

📚 Belknap SM, Aslam I, Kiguradze T, et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatol. 2015;151(6):600-606. doi:10.1001/jamadermatol.2015.36 | PubMed

Caruso D, Abbiati F, Giatti S, et al. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015;146:74-79. doi:10.1016/j.jsbmb.2014.03.012 | PubMed

🐀 🧬 Chávez B, Ramos L, García-Becerra R, Vilchis F. Hamster SRD5A3 lacks steroid 5α-reductase activity in vitro. Steroids. 2015;94:41–50. doi:10.1016/j.steroids.2014.11.005 | PubMed

Descazeaud A, de La Taille A, Giuliano F, Desgrandchamps F, Doridot G. [Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia]. Prog Urol. 2015;25(3):115-127. doi:10.1016/j.purol.2014.12.003 | PubMed

Ganzer CA, Jacobs AR, Iqbal F. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Mens Health. 2015;9(3):222-228. doi:10.1177/1557988314538445 | PubMed

Ge R, Wang Z, Bechis SK, et al. DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. Am J Pathol. 2015;185(3):870–882. doi:10.1016/j.ajpath.2014.11.020 | PubMed

Glina S, Roehrborn CG, Esen A, et al. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. J Sex Med. 2015;12(1):129-138. doi:10.1111/jsm.12714PubMed

Irwig MS. Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2015;22(3):248-253. doi:10.1097/MED.0000000000000158 | PubMed

Lin WL, Hsieh YW, Lin CL, Sung FC, Wu CH, Kao CH. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia. Clin Endocrinol (Oxf). 2015 Apr;82(4):503-8. doi:10.1111/cen.12599 | PubMed

🐀 Litim N, Bourque M, Al Sweidi S, Morissette M, Di Paolo T. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson’s disease. Neuropharmacology. 2015;97:86‐94. doi:10.1016/j.neuropharm.2015.05.015 | PubMed

🐀 Livingstone DE, Barat P, Di Rollo EM, et al. 5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. Diabetes. 2015;64(2):447-458. doi:10.2337/db14-0249 | PubMed

Mladenović D, Petronijević N, Stojković T, Velimirović M, Jevtić G, Hrnčić D, Radosavljević T, Rašić-Marković A, Maksić N, Djuric D, Stanojlović O. Finasteride Has Regionally Different Effects on Brain Oxidative Stress and Acetylcholinesterase Activity in Acute Thioacetamide-Induced Hepatic Encephalopathy in Rats. PLoS One. 2015 Aug 4;10(8):e0134434. doi:10.1371/journal.pone.0134434 | PubMed

Moore TJ. Finasteride and the Uncertainties of Establishing Harms. JAMA Dermatol. 2015 Jun;151(6):585-6. doi:10.1001/jamadermatol.2015.37 | PubMed

Narasimhalu CR. Randomized Questionnaire Based Case-Control Research Study on Evaluation of Sexual Function in Indian Patients Taking Oral Finasteride for Androgenetic Alopecia. Dermatol Ther (Heidelb). 2015;5(4):231-234. doi:10.1007/s13555-015-0084-3 | PubMed

Nasiri M, Nikolaou N, Parajes S, et al. 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes. Endocrinology. 2015;156(8):2863–2871. doi:10.1210/en.2015-1149 | PubMed

Perez-Mora N, Velasco C, Bermüdez F. Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men. Skinmed. 2015;13(3):179-183. PubMed

Stojanović N, Ignjatović I, Djenić N, Bogdanović D. Adverse Effects of Pharmacological Therapy of Benign Prostatic Hyperplasia on Sexual Function in Men. Srp Arh Celok Lek. 2015;143(5-6):284–289. doi:10.2298/sarh1506284s | PubMed

Traish, A.M. The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being. Curr Sex Health Rep. 2015;7:210–219. doi:10.1007/s11930-015-0061-y

Traish AM, Haider KS, Doros G, Haider A. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Horm Mol Biol Clin Investig. 2015;23(3):85-96. doi:10.1515/hmbci-2015-0015 | PubMed

Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know? Rev Endocr Metab Disord. 2015;16(3):177-198. doi:10.1007/s11154-015-9319-y | PubMed

2014

↑ back to top

Bauman TM, Sehgal PD, Johnson KA, et al. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues. Prostate. 2014;74(9):923–932. doi:10.1002/pros.22810 | PubMed

Bissegger S, Martyniuk CJ, Langlois VS. Transcriptomic profiling in Silurana tropicalis testes exposed to finasteride. Gen Comp Endocrinol. 2014;203:137–145. doi:10.1016/j.ygcen.2014.01.018 | PubMed

Casabé A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014;191(3):727-733. doi:10.1016/j.juro.2013.09.059 | PubMed

🧬 Cecchin E, De Mattia E, Mazzon G, Cauci S, Trombetta C, Toffoli G. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. Int J Biol Markers. 2014;29(4):e310–e316. doi:10.5301/jbm.5000095 | PubMed

Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014;2014:329456. doi:10.1155/2014/329456 | PubMed

Di Loreto C, La Marra F, Mazzon G, Belgrano E, Trombetta C, Cauci S. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia. PLoS One. 2014;9(6):e100237. Published 2014 Jun 24. doi:10.1371/journal.pone.0100237 | PubMed

Duijnhoven RG, Straus SM, Souverein PC, et al. Long-term use of 5α-reductase inhibitors and the risk of male breast cancer. Cancer Causes Control. 2014;25(11):1577-1582. doi:10.1007/s10552-014-0455-6 | PubMed

Famenini S, Gharavi NM, Beynet DP. Finasteride associated melasma in a Caucasian male. J Drugs Dermatol. 2014;13(4):484-486. PubMed | Journal site

Fwu CW, Eggers PW, Kirkali Z, McVary KT, Burrows PK, Kusek JW. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol. 2014;191(6):1828-1834. doi:10.1016/j.juro.2013.12.014 | PubMed

Fwu CW, Eggers PW, Kirkali Z, McVary KT, Burrows PK, Kusek JW. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol. 2014;191(6):1828-1834. doi:10.1016/j.juro.2013.12.014 | PubMed

📚 Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554-1566. doi:10.1111/jsm.12525 | PubMed

Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–498.e3. doi:10.1016/j.jaad.2013.10.049 | PubMed

📚 Gupta AK, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat. 2014;25(2):156-161. doi:10.3109/09546634.2013.813011 | PubMed

Hogan C, Le Noury J, Healy D, Mangin D. One hundred and twenty cases of enduring sexual dysfunction following treatment. Int J Risk Saf Med. 2014;26(2):109-116. doi:10.3233/JRS-140617 | PubMed

Irwig MS. Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects. JAMA Dermatol. 2014;150(12):1361-1363. doi:10.1001/jamadermatol.2014.1830 | PubMed

Irwig MS. Persistent Sexual and Nonsexual Adverse Effects of Finasteride in Younger Men. Sex Med Rev. 2014;2(1):24-35. doi:10.1002/smrj.19 | PubMed

Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53(11):1351-1357. doi:10.1111/ijd.12060 | PubMed

🐀 Modol L, Casas C, Navarro X, et al. Neonatal finasteride administration alters hippocampal α4 and δ GABAAR subunits expression and behavioural responses to progesterone in adult rats. Int J Neuropsychopharmacol. 2014;17(2):259-273. doi:10.1017/S1461145713000989 | PubMed

Ryu HJ, Kwon DY. Reversible myopathy and ophthalmoparesis after low-dose finasteride administration for androgenic alopecia. Dermatol Surg. 2014;40(5):595-597. doi:10.1111/dsu.12458 | PubMed

Singh MK, Avram M. Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring? J Clin Aesthet Dermatol. 2014;7(12):51-55. PubMed

🐀 Singh S, Moksha L, Sharma N, Titiyal JS, Biswas NR, Velpandian T. Development and evaluation of animal models for sex steroid deficient dry eye. J Pharmacol Toxicol Methods. 2014;70(1):29–34. doi:10.1016/j.vascn.2014.03.004 | PubMed

Traish AM, Guay AT, Zitzmann M. 5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis. Horm Mol Biol Clin Investig. 2014;20(3):73-80. doi:10.1515/hmbci-2014-0025 | PubMed

Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors’ therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014;55(6):367-379. doi:10.4111/kju.2014.55.6.367 | PubMed

Varothai, S, Bergfeld, WF. Androgenetic Alopecia: An Evidence-Based Treatment Update. Am J Clin Dermatol.2014;15:217–230. doi:10.1007/s40257-014-0077-5

Yim E, Nole KL, Tosti A. 5α-Reductase inhibitors in androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2014;21(6):493-498. doi:10.1097/MED.0000000000000112 | PubMed

2013

↑ back to top

Bird ST, Brophy JM, Hartzema AG, Delaney JA, Etminan M. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride. J Urol. 2013;190(5):1811-1814. doi:10.1016/j.juro.2013.04.132 | PubMed

Collier R. Propecia lawsuits: the lasting effects of delayed drug warnings. CMAJ. 2013;185(10):E455-E456. doi:10.1503/cmaj.109-4488 | PubMed

🐀 Frau R, Pillolla G, Bini V, Tambaro S, Devoto P, Bortolato M. Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice. Psychoneuroendocrinology. 2013 Apr;38(4):542-51. doi:10.1016/j.psyneuen.2012.07.014 | PubMed

Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf. 2013;12(1):81-90. doi:10.1517/14740338.2013.742885 | PubMed

Hotaling JM. Finasteride and male infertility: a case for prospective collaborative research databases?. Fertil Steril. 2013;100(6):1528–1529. doi:10.1016/j.fertnstert.2013.08.023 | PubMed

Irwig MS. Decreased alcohol consumption among former male users of finasteride with persistent sexual side effects: a preliminary report. Alcohol Clin Exp Res. 2013;37(11):1823-1826. doi:10.1111/acer.12177 | PubMed

Melcangi RC, Caruso D, Abbiati F, et al. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med. 2013;10(10):2598-2603. doi:10.1111/jsm.12269 | PubMed

Millsop JW, Heller MM, Eliason MJ, Murase JE. Dermatological medication effects on male fertility. Dermatol Ther. 2013;26(4):337–346. doi:10.1111/dth.12069 | PubMed

🐀 Mòdol L, Darbra S, Vallèe M, Pallarès M. Alteration of neonatal Allopregnanolone levels affects exploration, anxiety, aversive learning and adult behavioural response to intrahippocampal neurosteroids. Behav Brain Res. 2013;241:96-104. doi:10.1016/j.bbr.2012.11.043 | PubMed

Motofei IG, Rowland DL, Georgescu SR, et al. A pilot study on the sexual side effects of finasteride as related to hand preference for men undergoing treatment of male pattern baldness. BJU Int. 2013;111(4 Pt B):E221-6. doi:10.1111/j.1464-410X.2012.11580.x | PubMed

Nusbaum AG, Rose PT, Nusbaum BP. Nonsurgical therapy for hair loss. Facial Plast Surg Clin North Am. 2013 Aug;21(3):335-42. doi:10.1016/j.fsc.2013.04.003 | PubMed

Şalvarci A, Istanbulluoğlu O. Secondary infertility due to use of low-dose finasteride. Int Urol Nephrol. 2013;45(1):83-85. doi:10.1007/s11255-012-0315-9 | PubMed

Samplaski MK, Lo K, Grober E, Jarvi K. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril. 2013;100(6):1542–1546. doi:10.1016/j.fertnstert.2013.07.2000 | PubMed

Stanczyk FZ, Azen CG, Pike MC. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013;138:10–16. doi:10.1016/j.jsbmb.2013.02.015 | PubMed

[Comment] Traish AM, Morgentaler A. Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013;138:462. doi:10.1016/j.jsbmb.2013.06.013 | PubMed

📚 Trost L, Saitz TR, Hellstrom WJ. Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review. Sex Med Rev. 2013;1(1):24-41. doi:10.1002/smrj.3 | PubMed

🐀 Zhang MG, Wang XJ, Shen ZJ, Gao PJ. Long-term oral administration of 5α-reductase inhibitor attenuates erectile function by inhibiting autophagy and promoting apoptosis of smooth muscle cells in corpus cavernosum of aged rats. Urology. 2013;82(3):743.e9–743.e7.43E15. doi:10.1016/j.urology.2013.02.045 | PubMed

🐀 Zhao XF, Yang Y, Wang W, Qiu Z, Zhang P, Wang B. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs. Chin Med J (Engl). 2013;126(4):711–715. doi:10.3760/cma.j.issn.0366-6999.20122496 | PubMed

2012

↑ back to top

Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012;2012:530121. doi:10.1155/2012/530121 | PubMed

Berthold D, Lhermitte B, Uffer M, Doerfler A. Finasteride-related Leydig cell tumour: report of a case and literature review. Andrologia. 2012;44 Suppl 1:836-837. doi:10.1111/j.1439-0272.2011.01214.x | PubMed

Bortolato M, Cannas A, Solla P, Bini V, Puligheddu M, Marrosu F. Finasteride attenuates pathological gambling in patients with Parkinson disease. J Clin Psychopharmacol. 2012 Jun;32(3):424-5. doi:10.1097/JCP.0b013e3182549c2a | PubMed

Corona G, Rastrelli G, Maseroli E, et al. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction. J Endocrinol Invest. 2012;35(10):915-920. doi:10.3275/8510

Devoto P, Frau R, Bini V, Pillolla G, Saba P, Flore G, Corona M, Marrosu F, Bortolato M. Inhibition of 5α-reductase in the nucleus accumbens counters sensorimotor gating deficits induced by dopaminergic activation. Psychoneuroendocrinology. 2012 Oct;37(10):1630-45. doi:10.1016/j.psyneuen.2011.09.018. Epub 2011 Oct 24. Free PMC Article

Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73(9):1220-1223. doi:10.4088/JCP.12m07887 | PubMed

Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012 Nov;9(11):2927-32. doi:10.1111/j.1743-6109.2012.02846.x | PubMed

[Comment] Canguven O, Talib RA. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2013;10(5):1441. doi:10.1111/jsm.12089 | Journal site

Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract. 2012;66(11):1052-1055. doi:10.1111/j.1742-1241.2012.03010.x

Kuehn BM. Prostate, baldness drugs linked to sexual dysfunction. JAMA. 2012;307(18):1903. doi:10.1001/jama.2012.4488 | PubMed

La Marra F, Di Loreto C, Mazzon G, et al. Preliminary evidence of a peculiar hormonal profile in men with adverse effects after use of finasteride against androgenetic alopecia. Am J Pathol. 2012;181:S8. Journal site

Mysore V. Finasteride and sexual side effects. Indian Dermatol Online J. 2012;3(1):62-65. doi:10.4103/2229-5178.93496

🐀 Oztekin CV, Gur S, Abdulkadir NA, et al. Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. J Sex Med. 2012;9(7):1773–1781. doi:10.1111/j.1743-6109.2012.02759.x | PubMed

Ricci G, Martinelli M, Luppi S, et al. Finasteride and fertility: case report and review of the literature. J Drugs Dermatol. 2012;11(12):1511–1513. doi:10.1111/dth.12069 | PubMed

Santo Domingo D, Stevenson ML, Auerbach J, Lerman J. Finasteride-induced pseudoporphyria. Arch Dermatol. 2011;147(6):747‐748. doi:10.1001/archdermatol.2011.144 | PubMed

Traish AM. 5α-reductases in human physiology: an unfolding story. Endocr Pract. 2012;18(6):965–975. doi:10.4158/EP12108.RA | PubMed

2011

↑ back to top

Chi BH, Kim SC. Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. Korean J Urol. 2011 Sep;52(9):632-6. doi:10.4111/kju.2011.52.9.632 | PubMed

Chiba K, Yamaguchi K, Li F, Ando M, Fujisawa M. Finasteride-associated male infertility. Fertil Steril. 2011;95(5):. doi:10.1016/j.fertnstert.2010.12.001 | PubMed

Goldstein I. An old problem with a new cause-5 alpha reductase inhibitors and persistent sexual dysfunction. J Sex Med. 2011;8(7):1829–1831. doi:10.1111/j.1743-6109.2011.02368.x | PubMed

[Comment] Uribe JF. Persistent sexual dysfunction and 5 alpha reductase inhibitors. J Sex Med. 2012;9(9):2475. doi:10.1111/j.1743-6109.2012.02676.x | PubMed

Hwang TIS. Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Urological Science. 2011;22(1):14-18. doi:10.1016/S1879-5226(11)60003-1

Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747-1753. doi:10.1111/j.1743-6109.2011.02255.x | PubMed

Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011 Aug;108(3):388-94. doi:10.1111/j.1464-410X.2011.10195.x | PubMed

🐀 Paris JJ, Brunton PJ, Russell JA, Walf AA, Frye CA. Inhibition of 5α-reductase activity in late pregnancy decreases gestational length and fecundity and impairs object memory and central progestogen milieu of juvenile rat offspring. J Neuroendocrinol. 2011;23(11):1079-1090. doi:10.1111/j.1365-2826.2011.02219.x | PubMed

🐀 Pinsky MR, Gur S, Tracey AJ, Harbin A, Hellstrom WJ. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011;8(11):3066–3074. doi:10.1111/j.1743-6109.2011.02425.x | PubMed

Rossi A, Cantisani C, Scarnò M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther. 2011;24(4):455–461. doi:10.1111/j.1529-8019.2011.01441.x | PubMed

Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8(3):872-884. doi:10.1111/j.1743-6109.2010.02157.x | PubMed

Tu HY, Zini A. Finasteride-induced secondary infertility associated with sperm DNA damage. Fertil Steril. 2011;95(6):2125.e13–2125.e14. doi:10.1016/j.fertnstert.2010.12.061 | PubMed

2010

↑ back to top

Darbra S, Pallarès M. Alterations in neonatal neurosteroids affect exploration during adolescence and prepulse inhibition in adulthood. Psychoneuroendocrinology. 2010;35(4):525-535. doi:10.1016/j.psyneuen.2009.08.020 | PubMed

Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?. Dermatol Ther. 2010;23(5):544-546. doi:10.1111/j.1529-8019.2010.01358.x | PubMed

📚 Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146(10):1141-1150. doi:10.1001/archdermatol.2010.256 | PubMed

Finasteride: male breast cancer. Prescrire Int. 2010;19(111):283. PubMed

Ramot Y, Czarnowicki T, Zlotogorski A. Finasteride induced Gynecomastia: Case report and Review of the Literature. Int J Trichology. 2009;1(1):27–29. doi:10.4103/0974-7753.51930 | PubMed

Römer B, Gass P. Finasteride-induced depression: new insights into possible pathomechanisms [published correction appears in J Cosmet Dermatol. 2011 Mar;10(1):85]. J Cosmet Dermatol. 2010;9(4):331-332. doi:10.1111/j.1473-2165.2010.00533.x | PubMed

🐀 Römer B, Pfeiffer N, Lewicka S, et al. Finasteride treatment inhibits adult hippocampal neurogenesis in male mice. Pharmacopsychiatry. 2010;43(5):174-178. doi:10.1055/s-0030-1249095 | PubMed

Wong AC, Mak ST. Finasteride-associated cataract and intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2011;37(7):1351‐1354. doi:10.1016/j.jcrs.2011.04.013 | PubMed

2009

↑ back to top

Anitha B, Inamadar AC, Ragunatha S. Finasteride-its impact on sexual function and prostate cancer. J Cutan Aesthet Surg. 2009;2(1):12-16. doi:10.4103/0974-2077.53093

🐀🧬 Duarte-Guterman P, Langlois VS, Hodgkinson K, et al. The aromatase inhibitor fadrozole and the 5-reductase inhibitor finasteride affect gonadal differentiation and gene expression in the frog Silurana tropicalis. Sex Dev. 2009;3(6):333-341. doi:10.1159/000280586 | PubMed

Dusková M, Hill M, Hanus M, Matousková M, Stárka L. Finasteride treatment and neuroactive steroid formation. Prague Med Rep. 2009;110(3):222-230. Journal site | PubMed

🐀 Serga, CNK. The Effect of Different Doses of Finasteride on Sperm Morphology and Motility and Reactive Oxygen Species Concentrations in Rats. Med J Cairo Univ. Sept 2009;77(1):439–447. PDF on semanticscholar.org

Smith AB, Carson CC. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009;5(3):535–545. doi:10.2147/tcrm.s6195 | PubMed

🐀 Yawno T, Hirst JJ, Castillo-Melendez M, Walker DW. Role of neurosteroids in regulating cell death and proliferation in the late gestation fetal brain. Neuroscience. 2009;163(3):838-847. doi:10.1016/j.neuroscience.2009.07.009 | PubMed

2008

↑ back to top

Amory JK, Anawalt BD, Matsumoto AM, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol. 2008;179(6):2333-2338. doi:10.1016/j.juro.2008.01.145 | PubMed

Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med. 2008;5(12):2917-2924. doi:10.1111/j.1743-6109.2008.01001.x | PubMed

Hamdy FC, Rouprêt M. [The PCPT trial]. Prog Urol. 2008;18 Suppl 3:S40-3. doi:10.1016/S1166-7087(08)70512-8

Koethe D, Bortolato M, Piomelli D, Leweke FM. Improvement of general symptoms in a chronic psychotic patient treated with finasteride: case report. Pharmacopsychiatry. 2008 May;41(3):115-6. doi:10.1055/s-2008-1058110 | PubMed. Erratum in: Pharmacopsychiatry. 2011 Jun;44(4):163.

Liu KE, Binsaleh S, Lo KC, Jarvi K. Propecia-induced spermatogenic failure: a report of two cases. Fertil Steril. 2008;90(3):. doi:10.1016/j.fertnstert.2007.08.026 | PubMed

🐀 Martín-García E, Darbra S, Pallarés M. Neonatal finasteride induces anxiogenic-like profile and deteriorates passive avoidance in adulthood after intrahippocampal neurosteroid administration. Neuroscience. 2008;154(4):1497-1505. doi:10.1016/j.neuroscience.2008.04.062 | PubMed

Sarvis JA, Thompson IM. Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice. Curr Oncol Rep. 2008;10(6):529-532. doi:10.1007/s11912-008-0080-1 | PubMed

Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS. Five-alpha-reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008;(2):CD007091. doi:10.1002/14651858.CD007091

2007

↑ back to top

Al Hammadi A, Asai Y, Patt ML, Sasseville D. Erythema annulare centrifugum secondary to treatment with finasteride. J Drugs Dermatol. 2007;6(4):460-463. PubMed

Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men [published correction appears in J Clin Endocrinol Metab. 2007 Nov;92(11):4379]. J Clin Endocrinol Metab. 2007;92(5):1659–1665. doi:10.1210/jc.2006-2203 | PubMed

Bortolato M, Muroni A, Marrosu F. Treatment of Tourette’s syndrome with finasterideAm J Psychiatry. 2007 Dec;164(12):1914-5. doi:10.1176/appi.ajp.2007.07060978 | PubMed

Finasteride: new indication. Benign prostatic hypertrophy: sexual disorders. Prescrire Int. 2007;16(90):147. Journal site

Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99(13):1025-1035. doi:10.1093/jnci/djm023 | PubMed

Mondaini N, Gontero P, Giubilei G, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med. 2007;4(6):1708-1712. doi:10.1111/j.1743-6109.2007.00563.x | PubMed

Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29(1):17-25. doi:10.1016/j.clinthera.2007.01.018 | PubMed

2006

↑ back to top

🐀 de Brito Faturi C, Teixeira-Silva F, Leite JR. The anxiolytic effect of pregnancy in rats is reversed by finasteride. Pharmacol Biochem Behav. 2006;85(3):569-574. doi:10.1016/j.pbb.2006.10.011 | PubMed

Carson CC. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int. 2006;97 Suppl 2:39-43; discussion 44-5. doi:10.1111/j.1464-410X.2006.06105.x

Finn DA, Beadles-Bohling AS, Beckley EH, et al. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev. 2006;12(1):53-76. doi:10.1111/j.1527-3458.2006.00053.x

Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006;97 Suppl 2:34-38; discussion 44-5. doi:10.1111/j.1464-410X.2006.06104.x

🐀 Mann PE. Finasteride delays the onset of maternal behavior in primigravid rats. Physiol Behav. 2006;88(4-5):333-338. doi:10.1016/j.physbeh.2006.04.008 | PubMed

Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther. 2006;28(1):13-25. doi:10.1016/j.clinthera.2006.01.004

Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol. 2006;6:7. doi:10.1186/1472-6904-6-7 | PubMed

🐀 Robaire B, Henderson NA. Actions of 5alpha-reductase inhibitors on the epididymis. Mol Cell Endocrinol. 2006;250(1-2):190–195. doi:10.1016/j.mce.2005.12.044 | PubMed

Ryu HK, Kim KM, Yoo EA, Sim WY, Chung BC. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration. Br J Dermatol. 2006;154(4):730‐734. doi:10.1111/j.1365-2133.2005.07072.x | PubMed

2005

↑ back to top

Djavan B, Milani S, Fong YK. Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia. Expert Opin Pharmacother. 2005;6(2):311-317. doi:10.1517/14656566.6.2.311

Kuritzky L. Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting. Compr Ther. 2005;31(3):194-208. doi:10.1385/comp:31:3:194

Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol. 2005;7(4):203-210. PubMed

McVary KT. Sexual Function and α-Blockers. Rev Urol. 2005;7(Suppl 8):S3-S11. PubMed

Paick SH, Meehan A, Lee M, Penson DF, Wessells H. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study. J Urol. 2005;173(3):903-907. doi:10.1097/01.ju.0000152088.00361.a7

🐀 Ribeiro CM, Pereira OC. 5alpha-reductase 2 inhibition impairs brain defeminization of male rats: reproductive aspects. Pharmacol Biochem Behav. 2005;82(1):228-235. doi:10.1016/j.pbb.2005.08.015

Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47(6):824–837. doi:10.1016/j.eururo.2004.12.013 | PubMed

📚 Thomson A. Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia. Core Evid. 2005;1(2):143-156. PubMed

🧬 Wakisaka N, Taira Y, Ishikawa M, et al. Effectiveness of finasteride on patients with male pattern baldness who have different androgen receptor gene polymorphism. J Investig Dermatol Symp Proc. 2005;10(3):293-294. doi:10.1111/j.0022-202X.2005.10123.x | PubMed

2004

↑ back to top

Glina S, Neves PA, Saade R, Netto NR Jr, Soares JB, Galuppo AG. Finasteride-associated male infertility. Rev Hosp Clin Fac Med Sao Paulo. 2004 Aug;59(4):203-5. doi:10.1590/s0041-87812004000400009 | PubMed

Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol. 2004;14(3):143-149. doi:10.1097/00042307-200405000-00002 | PubMed

Pitts WR Jr. Finasteride (Propecia) and the promotion of high-grade prostate cancer. Arch Dermatol. 2004;140(7):885‐886. doi:10.1001/archderm.140.7.885-b | PubMed

Tosti A, Pazzaglia M, Soli M, et al. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia. Arch Dermatol. 2004;140(7):857-858. doi:10.1001/archderm.140.7.857 | PubMed

2003

↑ back to top

Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol. 2002;29(10):665–669. doi:10.1111/j.1346-8138.2002.tb00200.x | PubMed

[Comment] Pope JE, Makela EH. Response to article “Depression circumstantially related to the administration of finasteride for androgenetic alopecia” (J Dermatol, 29, 665-669, 2002). J Dermatol. 2003;30(11):837–844. doi:10.1111/j.1346-8138.2003.tb00488.x | PubMed

🐀 Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 2003;74(2):393-406. doi:10.1093/toxsci/kfg128

Carbone DJ, Hodges S. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res. 2003;15(4):299-306. doi:10.1038/sj.ijir.3901017

Kassabian VS. Sexual function in patients treated for benign prostatic hyperplasia. Lancet. 2003;361(9351):60-62. doi:10.1016/S0140-6736(03)12164-2 | PubMed

Larson TR. Current treatment options for benign prostatic hyperplasia and their impact on sexual function. Urology. 2003;61(4):692-698. doi:10.1016/s0090-4295(02)02552-9

Lowe FC, McConnell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 2003;61(4):791-796. doi:10.1016/s0090-4295(02)02548-7

McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–2398. doi:10.1056/NEJMoa030656 | PubMed

Roehrborn CG, Lee M, Meehan A, Waldstreicher J, Group PS. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology. 2003;62(5):894-899. doi:10.1016/s0090-4295(03)00661-7

Sadeghi-Nejad H, Sherman N, Lue J. Comparison of finasteride and alpha-blockers as independent risk factors for erectile dysfunction. Int J Clin Pract. 2003;57(6):484-487. PubMed

Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. doi:10.1056/NEJMoa030660 | PubMed

Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol. 2003;44(6):650-655. doi:10.1016/j.eururo.2003.11.001

Wessells H, Roy J, Bannow J, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003;61(3):579-584. doi:10.1016/s0090-4295(02)02401-9

Whiting DA, Olsen EA, Savin R, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003;13(2):150-160. PubMed

2002

↑ back to top

📚 Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol. 2002;2:14. doi:10.1186/1471-2490-2-14

Ferrando J, Grimalt R, Alsina M, Bulla F, Manasievska E. Unilateral gynecomastia induced by treatment with 1 mg of oral finasteride. Arch Dermatol. 2002;138(4):543‐544. doi:10.1001/archderm.138.4.543 | PubMed

🐀 Huynh H. Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol. 2002;20(6):1297-1303. PubMed

Leliefeld HH, Stoevelaar HJ, McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int. 2002;89(3):208-213. doi:10.1046/j.1464-4096.2001.01817.x

Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol. 2002;46(4):517–523. doi:10.1067/mjd.2002.120537 | PubMed

🐀 Rhoden EL, Gobbi D, Menti E, Rhoden C, Telöken C. Effects of the chronic use of finasteride on testicular weight and spermatogenesis in Wistar rats. BJU Int. 2002 Jun;89(9):961-3. doi:10.1046/j.1464-410x.2002.02785.x | PubMed

2001

↑ back to top

🐀 Dadras SS, Cai X, Abasolo I, Wang Z. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Gene Expr. 2001;9(4-5):183–194. doi:10.3727/000000001783992551 | PubMed

Kaplan SA. 5alpha-reductase inhibitors: what role should they play?. Urology. 2001;58(6 Suppl 1):65–70. doi:10.1016/s0090-4295(01)01347-4 | PubMed

Kaplan SA, Holtgrewe HL, Bruskewitz R, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology. 2001;57(6):1073–1077. doi:10.1016/s0090-4295(01)00985-2 | PubMed

O’Leary MP. Quality of life and sexuality: methodological aspects. Eur Urol. 2001;40 Suppl 3:13-18. doi:10.1159/000049886

Pole M, Koren G. Finasteride. Does it affect spermatogenesis and pregnancy?. Can Fam Physician. 2001;47:2469–2470. PMC full text | PubMed

Schulman C. Impact of treatment of BPH on sexuality. Prostate Cancer Prostatic Dis. 2001;4(S1):S12-S16. doi:10.1038/sj.pcan.4500541

Stoevelaar HJ, McDonnell J. Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations. Pharmacoeconomics. 2001;19(2):131-153. doi:10.2165/00019053-200119020-00003 | PubMed

Tosti A, Piraccini BM, Soli M. Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia. J Eur Acad Dermatol Venereol. 2001;15(5):418-421. doi:10.1046/j.1468-3083.2001.00315.x | PubMed

Wise GJ, Md EO. Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons. Curr Urol Rep. 2001;2(4):285-291. doi:10.1007/s11934-001-0065-1

2000

↑ back to top

Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol. 2000;38(1):2-19. doi:10.1159/000020246

Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000;143(4):804-810. doi:10.1046/j.1365-2133.2000.03780.x | PubMed

For older papers see Early research (1974–1999)